Evidence map›Paper›PMID 23761390›Full record

Trial reportJournal of psychopharmacology (Oxford, England)2013

Effects of escitalopram on attentional bias to cocaine-related stimuli and inhibitory control in cocaine-dependent subjects.

Shijing Liu, Scott D Lane, Joy M Schmitz, Kathryn A Cunningham, Vineeth P John, F Gerard Moeller

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of psychopharmacology (Oxford, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00732901 (Project 1), which is not on this map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00732901 phase2 / phase3completednot on this map

Project 1: Clinical Neurobiology of Serotonin and Addiction

TypeinterventionalSponsorVirginia Commonwealth UniversityRan2008 to 2013Enrolled160ConditionsCocaine DependenceArmsEscitalopram, Placebo
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Recent Advances in Attention Bias Modification for Substance Addictions.International journal of environmental research and public health · 2018
    Pooled it
  2. Review
  3. Similarities and Differences in Neurobiology.Advances in experimental medicine and biology · 2025
    Review
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Shijing LiuDepartment of Psychiatry and Behavioral Sciences, University of Texas Health Science Center at Houston, Houston, TX 77030, USA. shijing.liu@bcm.edu
Scott D Lane
Joy M Schmitz
Kathryn A Cunningham
Vineeth P John
F Gerard Moeller
The University of Texas Health Science Center at Houston · USThe University of Texas Medical Branch at Galveston · US

Funding

Translational MR Imaging in Cocaine Pharmacotherapy DevelopmentP50DA009262 · NIDA · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MOELLER, FREDERICK GERARD · 1994 to 2014
$26.9M
R25 SUPPLEMENT IN GENETIC EPIDEMIOLOGY EDUCATIONR25CA057730 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CHANG, SHINE · 1992 to 2016
$18.6M
Translational Center on Serotonin and Stimulant AddictionP20DA024157 · NIDA · UNIVERSITY OF TEXAS MED BR GALVESTON · PI CUNNINGHAM, KATHRYN A. · 2007 to 2012
$4.2M
Innovative Multidisciplinary Education: The Statistical Genetics of AddictionR25DA026120 · NIDA · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CHANG, SHINE, SHETE, SANJAY · 2010 to 2014
$1.5M
Addiction and the Neuropharmacology of PsychostimulantsK05DA020087 · NIDA · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI CUNNINGHAM, KATHRYN A. · 2005 to 2015
$1.3M
Serotonin, Impulsivity, and Substance AbuseK02DA000403 · NIDA · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MOELLER, FREDERICK GERARD · 2000 to 2011
$1.2M
NCI NIH HHS R25 CA057730NIDA NIH HHS K02 DA000403NIDA NIH HHS K02 DA00403NIDA NIH HHS K05 DA020087NIDA NIH HHS P20 DA024157NIDA NIH HHS P50 DA009262NIDA NIH HHS R25 DA026120
6 · The paper itself

Abstract

Key characteristics of cocaine dependence include attentional bias to cocaine cues and impaired inhibitory control. Studies suggest that serotonin modulates both cocaine cue reactivity and inhibitory control. We investigated effects of the selective serotonin reuptake inhibitor escitalopram on cocaine cue reactivity and inhibitory processes in cocaine-dependent subjects. In a double-blind placebo-controlled design, cocaine-dependent subjects received placebo (n=12) or escitalopram (n=11; 10 mg on days 1-3, 20 mg on days 4-24 and 10 mg on days 25-28) orally, once daily for 4 weeks. The cocaine Stroop and immediate memory task (IMT) were administered at baseline, days 1, 4, 11, 18 and 25 after placebo or escitalopram initiation. There were no significant between-group differences in baseline performance on the cocaine Stroop task or the IMT. On day 1 (acute phase), escitalopram produced a significantly greater decrease from baseline than placebo in attentional bias measured by cocaine Stroop task 5 hours post-dose. No significant changes from baseline in attentional bias were observed on subsequent test days (chronic phase). Inhibitory control as measured by IMT commission error rate was not significantly different between two groups in either the acute or chronic phase. Consistent with preclinical data, serotonin-modulating drugs like escitalopram may have acute effects on cocaine cue reactivity in human cocaine users.

Indexed as

AdultAttentionCitalopramCocaineCocaine-Related DisordersDouble-Blind MethodDrug UsersFemaleHumansMaleMemory, Short-TermSelective Serotonin Reuptake InhibitorsSerotoninCitalopramCocaineSelective Serotonin Reuptake InhibitorsSerotoninattentional biascocaine dependencecocaine Stroop taskEscitalopraminhibitory control

Identifiers

PMID23761390
PMCPMC4057042
OpenAlexW2154229467

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.